fbpx
Connect with us

News

Mable Therapy secures £3.1m Series A investment

Published

on

Mable Therapy, the digital health platform for children’s speech and language therapy and counselling services, has secured a £3.1m Series A investment from Gresham House Ventures.

The growth equity investor specialises in software and digitally driven businesses.

The investment will allow Mable to expand its tech offering and bolster its sales and marketing function to accelerate adoption in the education sector.

Founded in 2015, Mable provides access to a nationwide network of therapists who deliver live, 1-2-1 sessions through a bespoke online platform.

The platform has been designed to deliver improved therapeutic outcomes in a child-friendly environment.

Martha Currie, co-founder and clinical director at Mable Therapy, said: “Mable’s mission has always been to design therapy that puts children at its core, giving them the best chance to reach their full potential.

“Our pioneering technology has already helped thousands of families across the UK, and with this investment by Gresham House Ventures we can take this support even further.

“We also look forward to welcoming to the team Oli and Andrea, whose expertise will be instrumental as we continue to enhance and expand our service beyond the UK.”

Mable offers a direct-to-consumer service, as well as solutions for the education and healthcare sectors, where technology adoption is now seen as vital to address the growing unmet demand.

Over the past year, the company has delivered over 22,000 hours of therapy to over 3,000 children.

Benjamin Faulkner, associate director at Gresham House Ventures, said: “Mable’s technology transforms the lives of children in their crucial early stages of development.

“There is significant growth potential for Mable within the wider education and health sectors where its technology offering can drive meaningful efficiencies for public service providers.

“Martha and Elliot have built an excellent business that is backed by a wealth of clinical and technological expertise, and we are confident that Mable can continue to revolutionise the provision of this vital support across the UK.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories